Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Short-course Radiotherapy in Early Low Rectal Cancer
NCT05555888Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Dec 2022
- Primary completion
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in rectal cancer, sponsored by Fudan University. Primary endpoint: Complete Response Rate. Started Dec 2022; status: recruiting.
02
Drugs
toripalimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05555888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05555888.